DORAL, Florida, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces it is taking advantage of the new Farm Bill, which is set to legalize hemp cultivation and hemp-derived CBD and other products in the United States, by signing David Barbash as its chief sales officer beginning in 2019. Mr. Barbash is a results-driven sales and marketing professional with more than 20 years of new business development to his credit and is a proven negotiator, manager and motivator.
As has been widely publicized, the 2018 Farm Bill, being signed soon, removes hemp (including hemp-derived cannabinoids containing less than 0.3% THC) from the Controlled Substances Act and transfers oversight of these products from the Drug Enforcement Agency to the U.S. Department of Agriculture. The new classification will allow domestic banks to now accept and process transactions related to hemp-derived cannabinoid-based products and opens doors to commercialize these products in the mass market. New Frontier cannabis market data projects the American CBD market will reach $2.3 billion in revenues by 2022.
To further take advantage of and capitalize on this amazing new opportunity, the Company has transitioned Jill Buzan, ETST’s current chief sales officer, to direct the Company’s sales in Florida while Mr. Barbash steps in as the new chief sales officer beginning in 2019. Mr. Barbash will begin distributing ETST’s cannabinoid products through his nationwide small, medium and large chain retail accounts.
Mr. Barbash brings to the Company more than 25 years of natural products industry experience in both the U.S. and U.K. markets, having previously worked with niche forward-thinking companies like Health From The Sun/Arkopharma, Pure Essence Labs, and Harmonic Innerprizes. He brings extensive international experience and a high level of enthusiasm to his new role at ETST.
“It’s an incredibly exciting time at ETST, and I am very thankful to be heading up the team that is going to lead the way in the cannabinoid sector when it comes to product efficacy, purity and clinically backed effectiveness,” Mr. Barbash states. “In 2019, through increased distribution, an expanded sales force, further emphasis on education and projected record sales, we hope to provide a banner year for our customers, future customers and, ultimately, the consumer.”
Nickolas S. Tabraue, president, director and chairman of ETST, states, “We are thrilled to add David to our team, and we look forward to an exciting year as he steps in as ETST’s new chief sales officer. His expertise and enthusiasm will be tremendous assets as we ride the wave opportunity afforded by the legalization of hemp cultivation and hemp-derived CBD in the United States.”
About Earth Science Tech, Inc. (ETST)
Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma, in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical, Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary of Earth Science Tech, committed to the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the Company’s research and development efforts. The Company’s first medical device, Hygee™, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics, Inc.
Cannabis Therapeutics (“CTI”) is a wholly-owned subsidiary of Earth Science Tech, Inc. poised to take a leadership role in the development of new, leading-edge cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD (“KBD”) is a wholly-owned subsidiary of Earth Science Tech, Inc. that provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation, Inc.
Earth Science Foundation (“ESF”) is a wholly-owned subsidiary of Earth Science Tech, Inc. ESF is in the process of becoming a non-profit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech's effective CBD products to those in need. To learn more please visit: www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Nickolas S. Tabraue
President, Director & Chairman